Send to:

Choose Destination
See comment in PubMed Commons below
Curr Opin Pharmacol. 2006 Feb;6(1):98-102. Epub 2005 Dec 20.

Glutamate-based therapeutic approaches: allosteric modulators of metabotropic glutamate receptors.

Author information

  • 1Neuroscience Drug Discovery - Movement Disorders, Merck Research Laboratories, West Point, Pennsylvania 19486, USA.


Metabotropic glutamate receptors (mGluRs) have been proposed as novel targets for the treatment of a variety of disorders. Recently, highly selective allosteric modulators of the mGluRs have been developed by several groups. These allosteric compounds provide an unprecedented degree of selectivity for individual mGluRs, allowing for more detailed functional studies on the roles of these receptors. Furthermore, the allosteric approach avoids many of the hurdles associated with the development of direct agonists as drugs, and provides a clear path forward for clinical proof-of-concept studies. Currently, both positive allosteric modulators of mGluR2 and negative allosteric modulators of mGluR5 hold promise as novel anxiolytics, and positive allosteric modulators of mGluR4 appear to be an exciting new target for the treatment of Parkinson's disease.

[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk